Author:
Yu Jianpeng,Gao Wenlong,Gao Shen,Wen Simeng,Zhao Yang,Shang Zhiqun,Wang Yong,Niu Yuanjie
Funder
Tianjin Key Medical Discipline (Specialty) Construction Project
Natural Science Foundation of Tianjin City
Scientific Research Project of Tianjin Education Commission
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81
2. Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC et al (2021) Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin Cancer Res 27:3360–3369
3. Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A et al (2021) Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial. Prostate 81:326–338
4. Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD et al (2020) Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38(489–499):e483
5. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G et al (2017) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40–47
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献